Remedent, Inc.
REMI · OTC
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $1,307 | $2,000 | $2,999 | $3,399 |
| - Cash | $43 | $68 | $37 | $72 |
| + Debt | $15 | $0 | $0 | $0 |
| Enterprise Value | $1,279 | $1,932 | $2,963 | $3,327 |
| Revenue | $254 | $330 | $185 | $217 |
| % Growth | -23% | 78.1% | -14.7% | – |
| Gross Profit | $162 | $217 | $108 | $117 |
| % Margin | 63.6% | 65.7% | 58.2% | 54% |
| EBITDA | -$205 | $58 | -$30 | -$36 |
| % Margin | -80.5% | 17.6% | -16.3% | -16.7% |
| Net Income | -$219 | $36 | -$30 | -$62 |
| % Margin | -86.4% | 10.9% | -15.9% | -28.4% |
| EPS Diluted | -0.011 | 0.002 | -0.002 | -0.003 |
| % Growth | -711.1% | 220% | 51.6% | – |
| Operating Cash Flow | -$92 | $93 | -$78 | -$53 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$92 | $93 | -$78 | -$53 |